Page last updated: 2024-11-06

mitomycin and Diarrhea

mitomycin has been researched along with Diarrhea in 23 studies

Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.

Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.

Research Excerpts

ExcerptRelevanceReference
"To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial."9.14Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010)
"We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer."9.095-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001)
"No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy."9.08Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. ( André, AM; Bertino, JR; Conti, JA; Grossano, DD; Kemeny, NE; Saltz, LB, 1995)
"We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy."9.08Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. ( Bokemeyer, C; Daikeler, T; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Müller, C; Seeber, S, 1998)
"A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)."7.68Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993)
"Newer radiation techniques, and the application of continuous 5-FU exposure during radiation therapy using oral capecitabine may improve the treatment of anal cancer."5.17Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. ( Beijnen, JH; Boot, H; Cats, A; Deenen, MJ; Dewit, L; Schellens, JH, 2013)
"To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial."5.14Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010)
"We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer."5.095-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001)
"No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy."5.08Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. ( André, AM; Bertino, JR; Conti, JA; Grossano, DD; Kemeny, NE; Saltz, LB, 1995)
"We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy."5.08Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. ( Bokemeyer, C; Daikeler, T; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Müller, C; Seeber, S, 1998)
"Accurate description of current practice within advanced colorectal cancer (CRC) specialties were needed to inform an economic evaluation of the UGT1A1 pharmacogenetic test for irinotecan in the United Kingdom."3.76Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. ( Elliott, RA; Newman, WG; Payne, K; Shabaruddin, FH; Valle, JW, 2010)
"A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)."3.68Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993)
" We screened cancer patients' tumors for FA functional defects then aimed to establish the safety/feasibility of administering PARP inhibitors as monotherapy and combined with a DNA-breaking agent."2.82Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. ( Bekaii-Saab, T; Chen, A; Duan, W; Ji, J; Lustberg, M; Marshall, J; Rose, J; Schaaf, LJ; Shilo, K; Thurmond, J; Timmers, C; Villalona-Calero, MA; Westman, JA; Xiaobai, L; Zhao, W, 2016)
" Main adverse events grades 2/3/4 were (n): leukocytopenia 3/2/2, anemia 13/4/0, thrombocytopenia 3/1/0, nausea/vomiting 2/1/0, diarrhea 5/1/0, hand-foot-skin reaction 7/0/0."2.75Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. ( Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J, 2010)
" In conclusion, capecitabine can safely be combined with docetaxel (40 mg m(-2)) and mitomycin C (4 mg m(-2))."2.73Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. ( Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B, 2007)
"169 patients with radically resected gastric cancer were randomized to receive CPT-11 (180 mg/m2 day 1), leucovorin (100 mg/m2 days 1-2), FU (400-600 mg/m2 days 1-2, q 14; for four cycles; FOLFIRI regimen), followed by docetaxel (85 mg/m2 day 1), cisplatin (75 mg/m2 day 1, q 21; for three cycles; arm A), or MMC (8 mg/m2 days 1-2 as 2-hour infusion, q 42; for four cycles; arm B)."2.72Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. ( Agostana, B; Aitini, E; Ardizzoia, A; Ardizzoni, A; Bajetta, E; Bochicchio, AM; Bordonaro, R; Botta, M; Buzzoni, R; Cicero, G; Comella, G; Di Bartolomeo, M; Duro, M; Fagnani, D; Ferrario, E; Gevorgyan, A; Katia, D; Kildani, B; Mantovani, G; Mariani, L; Marini, G; Massidda, B; Mozzana, R; Oliani, C; Palazzo, S; Pinotti, G; Reguzzoni, G; Schieppati, G; Villa, E; Zilembo, N, 2006)
"Twenty-one stomach cancer patients and 34 colorectal cancer patients were registered in the study."2.67[Study of 5'-DFUR treatment as postoperative adjuvant chemotherapy for stomach and colorectal cancer. Tokai GATS Group (pilot study)]. ( Hachisuka, K; Honda, H; Honda, K; Maeda, A; Nakazato, H; Tsuruga, N; Yamaguchi, A; Yoshizaki, S; Yura, J, 1994)
" Patient acute gastrointestinal toxicity was recorded using Common Terminology Criteria of Adverse Events (CTCAE) diarrhoea grading."1.48Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes. ( Amor, H; Blakey, D; Chao, M; Guerrieri, M; Guiney, M; Ho, H; Macleod, C; Melven, L; Ng, M; Skelton, J; Subramanian, B, 2018)
"Grade 3-4 neutropenia was seen in 10/23 patients (43%)."1.46PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer. ( Beer, J; Bodis, S; Oehler, C; Vlachopoulou, V; von Moos, R; Zimmermann, M; Zwahlen, DR, 2017)
"Mitomycin C suppository was significantly less toxic compared with intravenous delivery, and higher rectal tissue concentrations were observed from 10 to 30 minutes (P < 0."1.30Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer. ( Ackerman, D; Galandiuk, S; Hofmeister, A; LaRocca, R; Lewis, RK; Myers, SR; Paris, KJ; Pokorny, RM; Wrightson, WR, 1997)
" Pharmacokinetic examination after intravenous injection of low-dose MMC (0."1.29A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics. ( Boku, N; Ishii, H; Kaneko, K; Kusada, O; Muro, K; Muto, M; Ohkuwa, M; Ohtsu, A; Sasaki, Y; Tajiri, H; Yoshida, S, 1996)

Research

Studies (23)

TimeframeStudies, this research(%)All Research%
pre-19902 (8.70)18.7374
1990's7 (30.43)18.2507
2000's6 (26.09)29.6817
2010's7 (30.43)24.3611
2020's1 (4.35)2.80

Authors

AuthorsStudies
Lukovic, J3
Hosni, A3
Liu, A3
Chen, J3
Tadic, T3
Patel, T3
Li, K3
Han, K3
Lindsay, P3
Craig, T3
Brierley, J3
Barry, A3
Wong, R3
Ringash, J3
Dawson, LA3
Kim, JJ3
Zimmermann, M1
Beer, J1
Bodis, S1
von Moos, R1
Vlachopoulou, V1
Zwahlen, DR1
Oehler, C1
Ng, M1
Ho, H1
Skelton, J1
Guerrieri, M1
Guiney, M1
Chao, M1
Blakey, D1
Macleod, C1
Amor, H1
Subramanian, B1
Melven, L1
Deenen, MJ1
Dewit, L1
Boot, H1
Beijnen, JH1
Schellens, JH1
Cats, A1
Villalona-Calero, MA1
Duan, W1
Zhao, W1
Shilo, K1
Schaaf, LJ1
Thurmond, J1
Westman, JA1
Marshall, J1
Xiaobai, L1
Ji, J1
Rose, J1
Lustberg, M1
Bekaii-Saab, T1
Chen, A1
Timmers, C1
Kruth, J1
Nissen, J1
Ernst, T2
Kripp, M2
Lukan, N2
Merx, K2
Hofmann, WK1
Hochhaus, A2
Hofheinz, RD2
Tebbutt, NC1
Wilson, K1
Gebski, VJ1
Cummins, MM1
Zannino, D1
van Hazel, GA1
Robinson, B1
Broad, A1
Ganju, V1
Ackland, SP1
Forgeson, G1
Cunningham, D1
Saunders, MP1
Stockler, MR1
Chua, Y1
Zalcberg, JR1
Simes, RJ1
Price, TJ1
Shabaruddin, FH1
Elliott, RA1
Valle, JW1
Newman, WG1
Payne, K1
Di Bartolomeo, M1
Buzzoni, R1
Mariani, L1
Ferrario, E1
Katia, D1
Gevorgyan, A1
Zilembo, N1
Bordonaro, R1
Bochicchio, AM1
Massidda, B1
Ardizzoia, A1
Ardizzoni, A1
Marini, G1
Aitini, E1
Schieppati, G1
Comella, G1
Pinotti, G1
Palazzo, S1
Cicero, G1
Bajetta, E1
Villa, E1
Fagnani, D1
Reguzzoni, G1
Agostana, B1
Oliani, C1
Kildani, B1
Duro, M1
Botta, M1
Mozzana, R1
Mantovani, G1
Gnad-Vogt, U1
Schultheis, B1
Glynne-Jones, R1
Meadows, H1
Wan, S1
Gollins, S1
Leslie, M1
Levine, E1
McDonald, AC1
Myint, S1
Samuel, L1
Sebag-Montefiore, D1
Inokuchi, K1
Hattori, T1
Taguchi, T1
Abe, O1
Ogawa, N1
Nakata, E1
Okajima, K1
Ishida, Y1
Munetomo, Y1
Gotoh, K1
Toyohara, M1
Miyazaki, H1
Matsunaga, S1
Maeura, Y1
Fujimura, T1
Francini, G1
Petrioli, R1
Aquino, A1
Gonnelli, S1
Conti, JA1
Kemeny, NE1
Saltz, LB1
André, AM1
Grossano, DD1
Bertino, JR1
Yamaguchi, A1
Maeda, A1
Hachisuka, K1
Yura, J1
Honda, K1
Honda, H1
Yoshizaki, S1
Tsuruga, N1
Nakazato, H1
Boku, N1
Ohtsu, A1
Muro, K2
Kaneko, K1
Muto, M1
Ohkuwa, M1
Ishii, H1
Sasaki, Y1
Tajiri, H1
Yoshida, S1
Kusada, O1
Pokorny, RM1
Wrightson, WR1
Lewis, RK1
Paris, KJ1
Hofmeister, A1
LaRocca, R1
Myers, SR1
Ackerman, D1
Galandiuk, S1
Hartmann, JT1
Harstrick, A1
Daikeler, T1
Kollmannsberger, C1
Müller, C1
Seeber, S1
Kanz, L1
Bokemeyer, C1
Sobrero, A1
Guglielmi, A1
Cirillo, M1
Recaldin, E1
Frassineti, GL1
Aschele, C1
Ravaioli, A1
Testore, P1
Caroti, C1
Gallo, L1
Pessi, MA1
Cortesi, E1
Turci, D1
Grossi, F1
Labianca, R1
Valentini, V1
Coco, C1
Cellini, N1
Picciocchi, A1
Fares, MC1
Rosetto, ME1
Mantini, G1
Morganti, AG1
Barbaro, B1
Cogliandolo, S1
Nuzzo, G1
Tedesco, M1
Ambesi-Impiombato, F1
Cosimelli, M1
Rotman, M1
Yamao, T1
Shirao, K1
Matsumura, Y1
Yamada, Y1
Goto, M1
Chin, K1
Shimada, Y1
Becouarn, Y1
Calabet, J1
Brunet, R1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent C[NCT04085250]Phase 2264 participants (Actual)Interventional2019-11-28Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

15 trials available for mitomycin and Diarrhea

ArticleYear
Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
    International journal of radiation oncology, biology, physics, 2013, Apr-01, Volume: 85, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; C

2013
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
    Journal of the National Cancer Institute, 2016, Volume: 108, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles;

2016
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
    Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Ne

2010
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-01, Volume: 28, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2010
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
    Oncology, 2006, Volume: 71, Issue:5-6

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2006
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
    British journal of cancer, 2007, Dec-03, Volume: 97, Issue:11

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Di

2007
EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
    International journal of radiation oncology, biology, physics, 2008, Sep-01, Volume: 72, Issue:1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus

2008
Postoperative adjuvant chemotherapy for gastric carcinoma. Analysis of data on 1805 patients followed for 5 years.
    Cancer, 1984, Jun-01, Volume: 53, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Moda

1984
[Combination therapy of high dose 5'-DFUR+MMC for advanced or recurrent gastric cancer. 5'-DFUR Joint Research Group in the Osaka District for Gastric Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration Schedule;

1995
Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.
    Cancer, 1995, Feb-01, Volume: 75, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1995
[Study of 5'-DFUR treatment as postoperative adjuvant chemotherapy for stomach and colorectal cancer. Tokai GATS Group (pilot study)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:5

    Topics: Administration, Oral; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea;

1994
Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer.
    Anti-cancer drugs, 1998, Volume: 9, Issue:5

    Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Colorectal Neoplasms; Diarrhea; Disease Progressio

1998
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
    British journal of cancer, 2001, Apr-20, Volume: 84, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Conjunctivitis; D

2001
Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies.
    International journal of radiation oncology, biology, physics, 2001, Oct-01, Volume: 51, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Combined

2001
Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response R

2001

Other Studies

8 other studies available for mitomycin and Diarrhea

ArticleYear
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr

2023
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr

2023
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr

2023
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr

2023
PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
    Acta oncologica (Stockholm, Sweden), 2017, Volume: 56, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem

2017
Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2018, Volume: 30, Issue:10

    Topics: Abdominal Cavity; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; An

2018
Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.
    British journal of cancer, 2010, Jul-27, Volume: 103, Issue:3

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin;

2010
Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C.
    Cancer chemotherapy and pharmacology, 1993, Volume: 32, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Drug Evalua

1993
A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics.
    Japanese journal of clinical oncology, 1996, Volume: 26, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow Diseas

1996
Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer.
    Diseases of the colon and rectum, 1997, Volume: 40, Issue:12

    Topics: Adenocarcinoma; Administration, Rectal; Animals; Antibiotics, Antineoplastic; Chromatography, High P

1997
Phase II study of a 5-fluorouracil, teniposide and mitomycin-C combination chemotherapy in advanced colorectal carcinomas.
    Tumori, 1988, Feb-29, Volume: 74, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Colonic Neoplasms; Diarrhea; D

1988